BSE Live
Nov 07, 16:01Prev. Close
1302.35
Open Price
1282.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 07, 15:55Prev. Close
1304.80
Open Price
1304.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1318.30 (75)
| Key Financial Ratios of Ipca Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 16.40 | 40.34 | 54.18 | 50.47 | 24.60 | |
| Diluted EPS (Rs.) | 16.40 | 40.34 | 54.18 | 50.47 | 24.60 | |
| Cash EPS (Rs.) | 20.00 | 53.91 | 68.55 | 62.09 | 33.97 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 69.08 | 252.62 | 234.83 | 189.50 | 148.20 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 69.08 | 252.62 | 234.83 | 189.50 | 148.20 | |
| Revenue from Operations/Share (Rs.) | 129.55 | 535.75 | 450.29 | 389.41 | 314.82 | |
| PBDIT/Share (Rs.) | 27.19 | 75.71 | 90.23 | 81.87 | 45.04 | |
| PBIT/Share (Rs.) | 23.45 | 59.84 | 77.27 | 70.09 | 35.10 | |
| PBT/Share (Rs.) | 21.27 | 47.35 | 69.85 | 61.72 | 29.80 | |
| Net Profit/Share (Rs.) | 16.26 | 38.04 | 55.59 | 50.31 | 24.01 | |
| NP After MI And SOA / Share (Rs.) | 16.40 | 40.34 | 54.18 | 50.47 | 24.60 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.98 | 14.13 | 20.03 | 21.02 | 14.30 | |
| PBIT Margin (%) | 18.10 | 11.16 | 17.16 | 17.99 | 11.15 | |
| PBT Margin (%) | 16.41 | 8.83 | 15.51 | 15.85 | 9.46 | |
| Net Profit Margin (%) | 12.54 | 7.10 | 12.34 | 12.91 | 7.62 | |
| NP After MI And SOA Margin (%) | 12.66 | 7.52 | 12.03 | 12.96 | 7.81 | |
| Return on Networth/Equity (%) | 23.74 | 15.96 | 23.07 | 26.63 | 16.59 | |
| Return on Capital Employed (%) | 17.58 | 10.72 | 14.32 | 16.99 | 10.36 | |
| Return on Assets (%) | 11.79 | 6.87 | 10.78 | 12.90 | 8.34 | |
| Total Debt/Equity (X) | 0.52 | 0.73 | 0.60 | 0.50 | 0.53 | |
| Asset Turnover Ratio (%) | 93.14 | 91.25 | 89.63 | 99.55 | 106.81 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.79 | 1.58 | 2.27 | 2.27 | 2.49 | |
| Quick Ratio (X) | 1.13 | 1.00 | 1.41 | 1.27 | 1.19 | |
| Inventory Turnover Ratio (X) | 4.27 | 4.37 | 4.22 | 4.12 | 4.21 | |
| Dividend Payout Ratio (NP) (%) | 17.04 | 27.37 | 14.74 | 14.86 | 22.35 | |
| Dividend Payout Ratio (CP) (%) | 13.88 | 19.64 | 11.89 | 12.04 | 15.91 | |
| Earnings Retention Ratio (%) | 82.96 | 72.63 | 85.26 | 85.14 | 77.65 | |
| Cash Earnings Retention Ratio (%) | 86.12 | 80.36 | 88.11 | 87.96 | 84.09 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 10.72 | 4.79 | 10.42 | 8.38 | 6.62 | |
| Interest Coverage Ratios (Post Tax) (%) | 10.72 | 4.79 | 10.42 | 8.38 | 6.62 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 3,821.12 | 1,270.14 | 1,870.32 | 1,736.55 | 1,063.94 | |
| EV/Net Operating Revenue (X) | 2.36 | 0.95 | 1.66 | 1.78 | 1.35 | |
| EV/EBITDA (X) | 11.23 | 6.71 | 8.26 | 8.48 | 9.45 | |
| MarketCap/Net Operating Revenue (X) | 2.08 | 0.61 | 1.35 | 1.55 | 1.11 | |
| Retention Ratios (%) | 82.95 | 72.62 | 85.25 | 85.13 | 77.64 | |
| Price/BV (X) | 3.91 | 1.30 | 2.59 | 3.18 | 2.36 | |
| Price/Net Operating Revenue | 2.08 | 0.61 | 1.35 | 1.55 | 1.11 | |
| Earnings Yield | 0.06 | 0.12 | 0.09 | 0.08 | 0.07 |
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
13.08.2025
Accumulate Ipca Laboratories; target of Rs 1525: Prabhudas Lilladher
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
03.06.2025
Ipca Labs Consolidated March 2025 Net Sales at Rs 2,246.69 crore, up 10.51% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
03.06.2025
Ipca Labs Consolidated March 2025 Net Sales at Rs 2,246.69 crore, up 10.51% Y-o-Y
04.03.2025
Ipca Labs Consolidated December 2024 Net Sales at Rs 2,245.37 crore, up 9.38% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher